论文部分内容阅读
Objective: Several phase Ⅲ studies demonstrated that, compared with traditional chemotherapy, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), as first-linetreatments, contributed to protracted progression-free survival (PFS) and higher responserate (RR) in inhibitor-sensitive EGFR mutant patients.